Buprenorphine Withdrawal Management

Introduction to Tapering

The American Society of Addiction Medicine recommends that patients should not be abruptly discontinued from Brixadi, as this constitutes unacceptable medical care and violates the principle of patient non-abandonment 1
Patients with opioid use disorder are unlikely to tolerate abstinence and face heightened overdose risk, and should be assessed before initiating taper 1
The Mayo Clinic recommends screening for depression, anxiety, and insomnia before and during the taper, as these symptoms commonly emerge or intensify during withdrawal 2, 3

The Mayo Clinic suggests beginning with very small dose reductions (5-10% of current dose) and adjusting based on patient tolerance 2, 3, 1
Each new dose should be 90% of the previous dose, and the taper rate is determined entirely by the patient's ability to tolerate it 1
Slow tapers may require several months to years, particularly for patients on long-term therapy 2, 3

The Mayo Clinic recommends proactively treating withdrawal symptoms with adjuvant medications and providing intensive clinical support 2, 3
Clonidine can be used for autonomic symptoms, and pain should be addressed separately as it may be a withdrawal symptom rather than exacerbation of original chronic pain 4, 1
Anxiety and depressive symptoms should be treated aggressively as they predict taper discontinuation 2, 3

The Mayo Clinic expects protracted withdrawal symptoms lasting months after buprenorphine elimination, including dysphoria, irritability, insomnia, anhedonia, and vague sense of being unwell 2, 3
These symptoms must be discussed with patients beforehand and either preempted or treated 2, 3

The Mayo Clinic suggests considering transitioning from Brixadi to daily sublingual buprenorphine/naloxone for more granular dose control during tapering 1
If taper fails or causes intolerable symptoms, resumption at a lower maintenance dose is appropriate, as this is preferable to complete discontinuation with subsequent relapse or use of illicit opioids 1

The Mayo Clinic recommends establishing a collaborative treatment plan with clear communication about goals, expectations, and contingency plans 1
Patients should be monitored closely with frequent follow-up during taper, and naloxone should be available and patients educated on overdose prevention 1, 4